eClinical Technology and Industy News

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

Excerpt from the Press Release:

FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the enrollment progress in the Phase II Part II clinical study of the Company’s ADHD medicine (ABV-1505). Since results on the first subject treated were reported on May 10, 2022, a total of 22 subjects have been enrolled in the study from a total of 32 subjects screened. One of the enrolled participants from the three arms completed the 8-week treatment per the study design.

The study, a randomized, double-blind, placebo-controlled study, titled “A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part II,” is expected to eventually enroll approximately 100 patients.

Five prestigious research hospitals in Taiwan and the research hospital at the University of California, San Francisco are participating in the study, which is a continuation of the Phase II Part I study of ABV-1505, completed successfully at UC, San Francisco and accepted by the U.S. Food & Drug Administration in October 2020.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?